Department of Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH 43614, USA.
The Toledo Clinic, Toledo, OH 43623, USA.
Future Oncol. 2019 Nov;15(33):3861-3876. doi: 10.2217/fon-2019-0374. Epub 2019 Oct 31.
Selective delivery of therapeutic agents into solid tumors has been a major challenge impeding the achievement of long-term disease remission and cure. The need to develop alternative drug delivery routes to achieve higher drug concentration in tumor tissue, reduce unwanted off-target side effects and thus achieve greater therapeutic efficacy, has resulted in an explosive body of research. are anaerobic, nonpathogenic, Gram-positive bacteria, commensal to the human gut that are a possible anticancer drug-delivery vehicle. In this review, we describe 's microbiology, current clinical applications, overview of the preclinical work investigating 's potential to deliver anticancer therapy, and review the different strategies used up to date. Finally, we discuss both current challenges and future prospects.
将治疗药物选择性递送到实体瘤一直是阻碍实现长期疾病缓解和治愈的主要挑战。需要开发替代药物递送途径，以在肿瘤组织中实现更高的药物浓度，减少不必要的脱靶副作用，从而实现更大的治疗效果，这导致了大量的研究。是一种厌氧的、非致病性的革兰氏阳性细菌，是人类肠道的共生菌，可能是一种抗癌药物递送载体。在这篇综述中，我们描述了的微生物学、当前的临床应用、调查其递送抗癌疗法潜力的临床前工作概述，并回顾了迄今为止使用的不同策略。最后，我们讨论了当前的挑战和未来的前景。
